Aprea Financial Statements From 2010 to 2025

Aprea Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 40.1 M 24 M 40 M Slightly volatile Other Current Liabilities 1.9 M 2 M 3.3 M Pretty Stable Total Current Liabilities 6.4 M 3.4 M 5.6 M Pretty Stable Accounts Payable 1.8 M 1.4 M 2.2 M Slightly volatile Cash 38.7 M 22.8 M 38.8 M Slightly volatile Other Assets 32.1 K 33.8 K 33.9 K Pretty Stable Net Receivables 6.7 K 7.5 K 8.2 K Slightly volatile Total Liabilities 4.4 M 4.7 M 26.8 M Pretty Stable Total Current Assets 39.9 M 23.6 M 39.8 M Slightly volatile Common Stock 5.2 K 5.5 K 57.8 K Slightly volatile Property Plant Equipment 2 K 2.1 K 102.7 K Very volatile Property Plant And Equipment Net 135.9 K 81.5 K 106.7 K Slightly volatile Non Current Assets Total 244.8 K 403.4 K 139.9 K Slightly volatile Non Currrent Assets Other 295.7 K 281.7 K 44.9 K Slightly volatile Cash And Short Term Investments 43.6 M 22.8 M 40.6 M Pretty Stable Common Stock Total Equity 18.1 K 19.1 K 80.3 K Slightly volatile Common Stock Shares Outstanding 5.8 M 5.5 M 1.5 M Slightly volatile Liabilities And Stockholders Equity 45.1 M 24 M 41.8 M Slightly volatile Non Current Liabilities Total 1.1 M 1.2 M 35.6 M Slightly volatile Capital Surpluse 136.6 M 266.1 M 108.1 M Slightly volatile Other Current Assets 689.9 K 726.3 K 1 M Slightly volatile Other Stockholder Equity 241.2 M 351 M 133.2 M Slightly volatile Property Plant And Equipment Gross 151.1 K 154 K 117.1 K Slightly volatile Net Working Capital 39.7 M 20.2 M 36.2 M Slightly volatile Capital Stock 5.2 K 5.5 K 76.6 K Slightly volatile Short and Long Term Debt Total 285.5 K 171.4 K 425.8 K Slightly volatile Current Deferred Revenue 423.2 K 476.1 K 519.1 K Slightly volatile
Aprea Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Selling General Administrative 8.1 M 6.5 M 6 M Slightly volatile Interest Income 865.4 K 1.3 M 737.1 K Pretty Stable Depreciation And Amortization 21.2 K 22.3 K 49.9 K Slightly volatile Other Operating Expenses 15 M 15.8 M 26.5 M Slightly volatile Research Development 8.9 M 9.4 M 20.1 M Pretty Stable Selling And Marketing Expenses 5.6 K 6.3 K 6.9 K Slightly volatile
Aprea Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Sale Purchase Of Stock 111.8 M 106.5 M 56.3 M Slightly volatile Depreciation 21.2 K 22.3 K 71.2 K Pretty Stable Total Cash From Financing Activities 17.5 M 14.8 M 22.1 M Very volatile End Period Cash Flow 39.9 M 22.9 M 37.7 M Slightly volatile Stock Based Compensation 465 K 489.4 K 2.3 M Slightly volatile Begin Period Cash Flow 42.6 M 21.6 M 35.3 M Slightly volatile Issuance Of Capital Stock 29.7 M 16.1 M 46.3 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 22.67 12.0643 27.6795 Slightly volatile Average Payables 2.5 M 1.5 M 2 M Very volatile Stock Based Compensation To Revenue 0.59 0.3257 0.724 Slightly volatile Capex To Depreciation 0.66 0.6935 2.8285 Slightly volatile Payables Turnover 0.0157 0.0165 0.0364 Slightly volatile Sales General And Administrative To Revenue 4.08 4.2984 13.1674 Slightly volatile Research And Ddevelopement To Revenue 10.62 6.2316 12.4965 Slightly volatile Capex To Revenue 0.0098 0.0103 0.1409 Slightly volatile Cash Per Share 3.94 4.147 62.2356 Pretty Stable Days Payables Outstanding 38.1 K 22.1 K 53.2 K Slightly volatile Income Quality 0.94 1.0461 0.8853 Pretty Stable Net Debt To EBITDA 2.35 1.7663 1.92 Very volatile Current Ratio 9.54 7.0147 7.4445 Slightly volatile Debt To Equity 0.0046 0.0044 0.0043 Slightly volatile Capex Per Share 0.0027 0.0028 0.0116 Slightly volatile Revenue Per Share 0.18 0.2727 0.1694 Slightly volatile Interest Debt Per Share 5.12 4.87 1.3891 Slightly volatile Debt To Assets 0.004 0.0039 0.0039 Slightly volatile Days Of Payables Outstanding 38.1 K 22.1 K 53.2 K Slightly volatile Ebt Per Ebit 0.97 0.905 1.083 Pretty Stable Total Debt To Capitalization 0.0046 0.0044 0.0043 Slightly volatile Debt Equity Ratio 0.0046 0.0044 0.0043 Slightly volatile Quick Ratio 9.54 7.0147 7.4445 Slightly volatile Net Income Per E B T 0.98 1.8 1.1359 Slightly volatile Cash Ratio 9.25 6.7986 7.2664 Slightly volatile Free Cash Flow Operating Cash Flow Ratio 0.8 1.0011 0.9893 Slightly volatile Fixed Asset Turnover 10.02 18.4316 7.5536 Slightly volatile Debt Ratio 0.004 0.0039 0.0039 Slightly volatile Price Sales Ratio 22.67 12.0643 27.6795 Slightly volatile Asset Turnover 0.0354 0.0627 0.0287 Slightly volatile Gross Profit Margin 1.09 0.9851 0.9941 Slightly volatile
Aprea Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 17.2 M 18.1 M 590 M Slightly volatile

Aprea Fundamental Market Drivers

Aprea Upcoming Events

About Aprea Therapeutics Financial Statements

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aprea Therapeutics is a strong investment it is important to analyze Aprea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aprea Therapeutics' future performance. For an informed investment choice regarding Aprea Stock, refer to the following important reports:

How To Invest In Aprea Details

Is Aprea Stock a good investment? Details

What is Aprea Therapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details